{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:48:12Z","timestamp":1791460092527,"version":"4.3.4"},"reference-count":94,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":2423,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thyroid dysfunction (TD) frequently occurs as an autoimmune complication of immune reconstitution therapy (IRT), especially in individuals with multiple sclerosis treated with alemtuzumab, a pan-lymphocyte depleting drug with subsequent recovery of immune cell numbers. Less frequently, TD is triggered by highly active antiretroviral therapy (HAART) in patients infected with human immunodeficiency virus (HIV), or patients undergoing bone-marrow\/hematopoietic-stem-cell transplantation (BMT\/HSCT). In both alemtuzumab-induced TD and HIV\/HAART patients, the commonest disorder is Graves\u2019 disease (GD), followed by hypothyroidism and thyroiditis; Graves\u2019 orbitopathy is observed in some GD patients. On the contrary, GD is rare post-BMT\/HSCT, where hypothyroidism predominates probably as a consequence of the associated radiation damage. In alemtuzumab-induced TD, the autoantibodies against the thyrotropin receptor (TRAb) play a major role, and 2 main aspects distinguish this condition from the spontaneous form: (1) up to 20% of GD cases exhibit a fluctuating course, with alternating phases of hyper- and hypothyroidism, due to the coexistence of TRAb with stimulating and blocking function; (2) TRAb are also positive in about 70% of hypothyroid patients, with blocking TRAb responsible for nearly half of the cases. The present guidelines will provide up-to-date recommendations and suggestions dedicated to all phases of IRT-induced TD: (1) screening before IRT (recommendations 1\u20133); (2) monitoring during\/after IRT (recommendations 4\u20137); (3) management of TD post-IRT (recommendations 8\u201317). The clinical management of IRT-induced TD, and in particular GD, can be challenging. In these guidelines, we propose a summary algorithm which has particular utility for nonspecialist physicians and which is tailored toward management of alemtuzumab-induced TD. However, we recommend prompt referral to specialist endocrinology services following diagnosis of any IRT-induced TD diagnosis, and in particular for pregnant women and those considering pregnancy.<\/jats:p>","DOI":"10.1159\/000500881","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T17:00:36Z","timestamp":1562259636000},"page":"173-185","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":62,"title":["2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy"],"prefix":"10.1530","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2926-0722","authenticated-orcid":false,"given":"Ilaria","family":"Muller","sequence":"first","affiliation":[{"name":"1Thyroid Research Group, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Moran","sequence":"additional","affiliation":[{"name":"2Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Lecumberri","sequence":"additional","affiliation":[{"name":"3Department of Endocrinology and Nutrition, La Paz University Hospital, IdiPAZ, Autonomous University of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Decallonne","sequence":"additional","affiliation":[{"name":"4Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Robertson","sequence":"additional","affiliation":[{"name":"5Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Jones","sequence":"additional","affiliation":[{"name":"6Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin\u00a0M.","family":"Dayan","sequence":"additional","affiliation":[{"name":"1Thyroid Research Group, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"issue":"6","key":"2026070712582166300_ref1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon-alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"24","key":"2026070712582166300_ref2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","article-title":"Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells","volume":"318","author":"Atkins","year":"1988","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"5","key":"2026070712582166300_ref3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0002-9343(01)01137-8","article-title":"Hypothyroidism in patients with multiple myeloma following treatment with thalidomide","volume":"112","author":"Badros","year":"2002","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"issue":"893","key":"2026070712582166300_ref4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/pmj.76.893.133","article-title":"Amiodarone-induced thyroid disorders: a clinical review","volume":"76","author":"Loh","year":"2000","journal-title":"Postgrad Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0032-5473","issn-type":"print"},{"issue":"5","key":"2026070712582166300_ref5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/0360-3016(95)00019-U","article-title":"Thyroid abnormalities after therapeutic external radiation","volume":"31","author":"Hancock","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys","ISSN":"https:\/\/id.crossref.org\/issn\/0360-3016","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1089\/thy.1998.8.909","article-title":"The effects of lithium therapy on thyroid and thyrotropin-releasing hormone","volume":"8","author":"Lazarus","year":"1998","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"7","key":"2026070712582166300_ref7","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/jc.2006-2822","article-title":"Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones","volume":"92","author":"Smit","year":"2007","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"21","key":"2026070712582166300_ref9","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8874","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref10","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"issue":"6","key":"2026070712582166300_ref11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.beem.2009.07.003","article-title":"Immune reconstitution syndrome and the thyroid","volume":"23","author":"Weetman","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/1521-690X","issn-type":"print"},{"issue":"8","key":"2026070712582166300_ref12","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features","volume":"103","author":"Pariani","year":"2018","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3050","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/01.md.0000159082.45703.90","article-title":"Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease","volume":"84","author":"Chen","year":"2005","journal-title":"Medicine (Baltimore)","ISSN":"https:\/\/id.crossref.org\/issn\/0025-7974","issn-type":"print"},{"issue":"9144","key":"2026070712582166300_ref16","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(05)60398-4","article-title":"Delayed occurrence of Graves\u2019 disease after immune restoration with HAART. Highly active antiretroviral therapy","volume":"352","author":"Gilquin","year":"1998","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"11","key":"2026070712582166300_ref17","first-page":"4254","article-title":"Sequential occurrence of thyroid autoantibodies and Graves\u2019 disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients","volume":"85","author":"Jubault","year":"2000","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/088922204773004879","article-title":"Graves\u2019 disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction","volume":"20","author":"French","year":"2004","journal-title":"AIDS Res Hum Retroviruses","ISSN":"https:\/\/id.crossref.org\/issn\/0889-2229","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/vim.2006.19.102","article-title":"Graves\u2019 disease as an immune reconstitution syndrome in an HIV-1-positive patient commencing effective antiretroviral therapy: case report and literature review","volume":"19","author":"Knysz","year":"2006","journal-title":"Viral Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0882-8245","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/01.aids.0000196173.42680.5f","article-title":"Graves disease: an increasingly recognized immune reconstitution syndrome","volume":"20","author":"Crum","year":"2006","journal-title":"AIDS","ISSN":"https:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"2026070712582166300_ref21","doi-asserted-by":"publisher","first-page":"743597","DOI":"10.1155\/2011\/743597","article-title":"Graves\u2019 Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy","volume":"2011","author":"Rasul","year":"2011","journal-title":"Aids Res Treat","ISSN":"https:\/\/id.crossref.org\/issn\/2090-1240","issn-type":"print"},{"issue":"12","key":"2026070712582166300_ref22","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1210\/jc.2004-0836","article-title":"Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence","volume":"89","author":"Ishiguro","year":"2004","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"9805","key":"2026070712582166300_ref23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref24","doi-asserted-by":"publisher","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","article-title":"Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases","volume":"13","author":"Memon","year":"2018","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J Clin Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-9142","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0340-5354","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3050","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref28","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1073\/pnas.97.10.5393","article-title":"Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy","volume":"97","author":"Fleury","year":"2000","journal-title":"Proc Natl Acad Sci USA","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"issue":"12","key":"2026070712582166300_ref29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/sj.bmt.1703291","article-title":"Relapse of Graves\u2019 disease after successful allogeneic bone marrow transplantation","volume":"28","author":"Hsiao","year":"2001","journal-title":"Bone Marrow Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"9","key":"2026070712582166300_ref30","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4967","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref31","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as Remission Induction Therapy in Beh\u00e7et Disease: A 20-year Experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"issue":"9","key":"2026070712582166300_ref32","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9[{LT}]1998::AID-ART348[{GT}]3.0.CO;2-T","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia","volume":"44","author":"Isaacs","year":"2001","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.leu.2403258","article-title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia","volume":"18","author":"Lundin","year":"2004","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"9955","key":"2026070712582166300_ref34","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial","volume":"384","author":"Haynes","year":"2014","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"5 Pt 1","key":"2026070712582166300_ref35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","article-title":"Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab","volume":"6","author":"Kirk","year":"2006","journal-title":"Am J Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/1600-6135","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13075-016-1188-6","article-title":"Immune reconstitution 20\u00a0years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies","volume":"18","author":"Cooles","year":"2016","journal-title":"Arthritis Res Ther","ISSN":"https:\/\/id.crossref.org\/issn\/1478-6354","issn-type":"print"},{"issue":"12","key":"2026070712582166300_ref37","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1089\/thy.2018.0232","article-title":"Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years","volume":"28","author":"Muller","year":"2018","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1210\/edrv-9-1-106","article-title":"Autoantibodies to the thyrotropin receptor","volume":"9","author":"Rees Smith","year":"1988","journal-title":"Endocr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref39","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cei.12980","article-title":"Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease","volume":"189","author":"Diana","year":"2017","journal-title":"Clin Exp Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/sj.bmt.1700771","article-title":"Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants","volume":"19","author":"Al-Fiar","year":"1997","journal-title":"Bone Marrow Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"11","key":"2026070712582166300_ref42","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2017-03-725671","article-title":"How I monitor long-term and late effects after blood or marrow transplantation","volume":"130","author":"Bhatia","year":"2017","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"8","key":"2026070712582166300_ref43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/s41409-018-0109-5","article-title":"Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes","volume":"53","author":"Farhadfar","year":"2018","journal-title":"Bone Marrow Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2141.1990.tb02548.x","article-title":"Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia","volume":"74","author":"Aldouri","year":"1990","journal-title":"Br J Haematol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"8","key":"2026070712582166300_ref45","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.bmt.1700955","article-title":"Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells","volume":"20","author":"Karthaus","year":"1997","journal-title":"Bone Marrow Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/sj.bmt.1701760","article-title":"Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves\u2019 disease","volume":"23","author":"Berisso","year":"1999","journal-title":"Bone Marrow Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.7326\/0003-4819-131-2-199907200-00023","article-title":"Graves disease after bone marrow transplantation","volume":"131","author":"Takeshita","year":"1999","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"7454","key":"2026070712582166300_ref48","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"issue":"6","key":"2026070712582166300_ref49","doi-asserted-by":"publisher","first-page":"123S","DOI":"10.1378\/chest.08-0654","article-title":"Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Guyatt","year":"2008","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"issue":"9191","key":"2026070712582166300_ref50","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"5","key":"2026070712582166300_ref52","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4158\/EP161208.GL","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules\u20142016 Update","volume":"22","author":"Gharib","year":"2016","journal-title":"Endocr Pract","ISSN":"https:\/\/id.crossref.org\/issn\/1530-891X","issn-type":"print"},{"issue":"5","key":"2026070712582166300_ref53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000478927","article-title":"European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: the EU-TIRADS","volume":"6","author":"Russ","year":"2017","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"key":"2026070712582166300_ref54","unstructured":"EMA\n          . Lemtrada: EPAR-Product-Information, https:\/\/www.ema.europa.eu\/documents\/product-information\/lemtrada-epar-product-information_en.pdf, 2018"},{"issue":"2","key":"2026070712582166300_ref55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1590\/2359-3997000000023","article-title":"Association between antiretrovirals and thyroid diseases: a cross-sectional study","volume":"59","author":"Silva","year":"2015","journal-title":"Arch Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/2359-3997","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/cit757","article-title":"Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Aberg","year":"2014","journal-title":"Clin Infect Dis","ISSN":"https:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"issue":"11","key":"2026070712582166300_ref57","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"11","key":"2026070712582166300_ref58","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"9856","key":"2026070712582166300_ref59","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"9856","key":"2026070712582166300_ref60","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"2026070712582166300_ref61","unstructured":"Miller\n              T\n            , HabekM, ColesA. Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate inci\u00acdence rates of malignancy. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting. September 10\u201313, 2014; Boston, MA, USA."},{"key":"2026070712582166300_ref62","first-page":"1117","article-title":"Detection of thyroid malignancies in alemtuzumab-treated patients in the multiple sclerosis clinical development program","volume":"21","author":"Lecumberri","year":"2015","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ecl.2014.05.006","article-title":"Thyroid abnormalities","volume":"43","author":"Weetman","year":"2014","journal-title":"Endocrinol Metab Clin North Am","ISSN":"https:\/\/id.crossref.org\/issn\/0889-8529","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/1055-9965.EPI-11-0823","article-title":"Long-term cancer risk among people diagnosed with AIDS during childhood","volume":"21","author":"Simard","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev","ISSN":"https:\/\/id.crossref.org\/issn\/1055-9965","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","article-title":"Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: a systematic review","volume":"8","author":"Cobucci","year":"2015","journal-title":"J Infect Public Health","ISSN":"https:\/\/id.crossref.org\/issn\/1876-0341","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jamaoncol.2017.2395","article-title":"Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy","volume":"4","author":"Mukhtar","year":"2018","journal-title":"JAMA Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/2374-2437","issn-type":"print"},{"key":"2026070712582166300_ref67","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-981-10-5765-6_10","article-title":"Malignancies in HIV-Infected and AIDS Patients","volume":"1018","author":"Ji","year":"2017","journal-title":"Adv Exp Med Biol","ISSN":"https:\/\/id.crossref.org\/issn\/0065-2598","issn-type":"print"},{"issue":"18","key":"2026070712582166300_ref68","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2017.0562","article-title":"Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"317","author":"Lin","year":"2017","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"5","key":"2026070712582166300_ref69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/cen.12427","article-title":"Graves\u2019 disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?","volume":"80","author":"Weetman","year":"2014","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13760-018-0883-2","article-title":"Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management","volume":"118","author":"Decallonne","year":"2018","journal-title":"Acta Neurol Belg","ISSN":"https:\/\/id.crossref.org\/issn\/0300-9009","issn-type":"print"},{"issue":"5","key":"2026070712582166300_ref71","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1210\/er.2009-0041","article-title":"Thyroid function and human reproductive health","volume":"31","author":"Krassas","year":"2010","journal-title":"Endocr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref72","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrendo.2017.93","article-title":"Thyroid disease in pregnancy: new insights in diagnosis and clinical management","volume":"13","author":"Korevaar","year":"2017","journal-title":"Nat Rev Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/1759-5029","issn-type":"print"},{"issue":"10","key":"2026070712582166300_ref73","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/thy.2006.0104","article-title":"Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism","volume":"17","author":"Erdo\u011fan","year":"2007","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"4","key":"2026070712582166300_ref75","doi-asserted-by":"publisher","first-page":"292","DOI":"10.14366\/usg.14059","article-title":"The value of the mean peak systolic velocity of the superior thyroidal artery in the differential diagnosis of thyrotoxicosis","volume":"34","author":"Kim","year":"2015","journal-title":"Ultrasonography","ISSN":"https:\/\/id.crossref.org\/issn\/2288-5919","issn-type":"print"},{"issue":"4","key":"2026070712582166300_ref76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"issue":"6","key":"2026070712582166300_ref77","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"6","key":"2026070712582166300_ref78","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1089\/thy.2015.0470","article-title":"The Natural History of Subclinical Hyperthyroidism in Graves\u2019 Disease: The Rule of Thirds","volume":"26","author":"Zhyzhneuskaya","year":"2016","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/thy.2012.0374","article-title":"Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa","volume":"23","author":"McLachlan","year":"2013","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref80","doi-asserted-by":"publisher","first-page":"CD003420","DOI":"10.1002\/14651858.CD003420.pub4","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev","ISSN":"https:\/\/id.crossref.org\/issn\/1469-493X","issn-type":"print"},{"issue":"12","key":"2026070712582166300_ref81","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11154-013-9248-6","article-title":"HIV and thyroid dysfunction","volume":"14","author":"Parsa","year":"2013","journal-title":"Rev Endocr Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/1389-9155","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref83","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000362597","article-title":"2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children","volume":"3","author":"Lazarus","year":"2014","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref84","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"2","key":"2026070712582166300_ref85","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1210\/er.21.2.168","article-title":"Management of Graves\u2019 ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref86","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/1521-690X","issn-type":"print"},{"issue":"7","key":"2026070712582166300_ref87","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"4","key":"2026070712582166300_ref88","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"3","key":"2026070712582166300_ref89","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1210\/jc.2014-3544","article-title":"Clinical challenges of thyroid eye disease in HIV-positive patients on highly active antiretroviral therapy","volume":"100","author":"Edmunds","year":"2015","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"key":"2026070712582166300_ref91","doi-asserted-by":"publisher","first-page":"1756286418773025","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther Adv Neurol Disorder","ISSN":"https:\/\/id.crossref.org\/issn\/1756-2856","issn-type":"print"},{"key":"2026070712582166300_ref92","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult Scler Relat Disord","ISSN":"https:\/\/id.crossref.org\/issn\/2211-0348","issn-type":"print"},{"issue":"1","key":"2026070712582166300_ref93","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40259-018-0327-9","article-title":"Monoclonal Antibodies for Multiple Sclerosis: an Update","volume":"33","author":"Graf","year":"2019","journal-title":"BioDrugs","ISSN":"https:\/\/id.crossref.org\/issn\/1173-8804","issn-type":"print"},{"key":"2026070712582166300_ref94","unstructured":"UNAIDS\n          . Trend of new HIV infections. AIDSinfo 2018;Available at: http:\/\/aidsinfo.unaids.org"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/500881","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/8\/4\/173\/34566\/etj500881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/8\/4\/173\/34566\/etj500881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:28:39Z","timestamp":1783445319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/8\/4\/173\/4680\/2019-European-Thyroid-Association-Guidelines-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000500881","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}